Berit Gravdehaug

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

Geeta Gulati, Siri Lagethon Heck, Anne Hansen Ree et al. · European Heart Journal · 2016 · 685 citations · Full text

Medicine, Oncology, Pharmacology +17

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol

Siri Lagethon Heck, Albulena Mecinaj, Anne Hansen Ree et al. · Circulation · 2021 · 152 citations · Full text

Medicine, Oncology, Pharmacology +16

Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study

Geeta Gulati, Siri Lagethon Heck, Helge Røsjø et al. · Journal of the American Heart Association · 2017 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial

Siri Lagethon Heck, Geeta Gulati, Anne Hansen Ree et al. · Cardiology · 2012 · 57 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy–Related Cardiac Dysfunction

Albulena Mecinaj, Geeta Gulati, Anne Hansen Ree et al. · JACC CardioOncology · 2024 · 45 citations · Full text

Medicine, Cardiology, Oncology +13